Scorecard › NFLX
NFLX analyst scorecard · Netflix
113 rating actions on NFLX in the last 12 months. Of 70 price targets that resolved, 12 were reached while they stood, 58 were replaced by the same firm first, and 0 fell short at their deadline. Ratings: 70% Buy-type, 29% Hold-type, 1% Sell-type. Consensus target $85, 37% above the last close.
Checked through 2026-10-29 · last close $62.06 (2026-10-29). Rebuilt every morning.
Targets reached while they stood
17.1% 12 of 70
Replaced before the deadline
82.9%
Short at the deadline
0.0%
Ratings vs XLC
4 of 23
Buy / Hold / Sell, 12 mo
70 / 29 / 1%
Consensus target
$85 +36.6%
What the Holds say: 27 Hold-type ratings on NFLX in the last 12 months carried a median target +9% from the price on the day; 22% sat below it.
The 6 upgrades on NFLX came after an average +3.3% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Rosenblatt | Neutral | 2026-10-21 | $71 | 2 | 5 | 7 | — |
| Oppenheimer | Outperform | 2026-10-21 | $80 | 0 | 5 | 5 | 0 of 1 |
| Guggenheim | Buy | 2026-10-21 | $78 | 1 | 6 | 7 | 1 of 1 |
| Wedbush | Outperform | 2026-10-21 | $80 | 0 | 7 | 7 | 1 of 1 |
| KeyBanc | Overweight | 2026-10-13 | $85 | 0 | 5 | 5 | 0 of 1 |
| Citigroup | Buy | 2026-10-21 | $85 | 0 | 1 | 1 | — |
| Wells Fargo | Underweight | 2026-09-18 | $57 | 1 | 0 | 1 | 0 of 1 |
| Baird | Outperform | 2026-07-22 | $90 | — | — | 0 | 0 of 1 |
| Barclays | Equal-Weight | 2026-10-21 | $65 | 1 | 2 | 3 | — |
| Morgan Stanley | Overweight | 2026-10-21 | $77 | 0 | 4 | 4 | 0 of 1 |
| Pivotal Research | Hold | 2026-10-22 | $65 | 1 | 1 | 2 | 1 of 1 |
| JPMorgan | Overweight | 2026-10-21 | $81 | 0 | 3 | 3 | — |
| UBS | Buy | 2026-10-21 | $100 | 0 | 2 | 2 | 0 of 1 |
| Evercore ISI Group | Outperform | 2026-10-21 | $90 | 0 | 2 | 2 | 1 of 1 |
| Bernstein | Outperform | 2026-10-21 | $80 | 0 | 2 | 2 | 0 of 1 |
| HSBC | Hold | 2026-09-22 | $76 | 1 | 0 | 1 | — |
| CFRA | Buy | 2026-03-06 | $115 | 0 | 1 | 1 | — |
| TD Cowen | Buy | 2026-10-21 | $100 | 0 | 2 | 2 | 0 of 1 |
| Piper Sandler | Overweight | 2026-10-21 | $78 | 1 | 2 | 3 | 0 of 1 |
| Goldman Sachs | Buy | 2026-07-17 | $94 | 0 | 2 | 2 | — |
| Citizens | Market Perform | 2026-10-21 | — | — | — | 0 | — |
| Wolfe Research | Peer Perform | 2026-10-22 | $95 | 1 | 0 | 1 | 0 of 1 |
| Needham | Hold | 2026-10-21 | $120 | 0 | 1 | 1 | 0 of 1 |
| Bank of America | Buy | 2026-10-21 | $90 | 0 | 2 | 2 | 0 of 1 |
| Argus Research | Buy | 2026-10-22 | $95 | 0 | 1 | 1 | — |
| BMO Capital | Outperform | 2026-10-16 | $125 | 0 | 1 | 1 | 0 of 1 |
| Deutsche Bank | Buy | 2026-09-29 | $95 | 1 | 0 | 1 | — |
| KGI Securities | Neutral | 2026-07-17 | $75 | 1 | 0 | 1 | — |
| Canaccord Genuity | Buy | 2026-01-21 | $125 | 0 | 1 | 1 | 0 of 1 |
| Freedom Broker | Buy | 2026-01-27 | $104 | 1 | 0 | 1 | — |
| Jefferies | Buy | 2025-12-11 | $134 | — | — | 0 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor NFLX carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-22 | Wolfe Research | Outperform → Peer Perform | downgrade | $67.05 | — | no target | -7.1% |
| 2026-10-22 | Argus Research | Buy | maintained | $67.05 | $95 | running to 2027-10-22 | -7.1% |
| 2026-10-22 | Pivotal Research | Hold | maintained | $67.05 | $65 | within 5% of price when set | -7.1% |
| 2026-10-21 | UBS | Buy | maintained | $65.04 | $100 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Citigroup | Buy | maintained | $65.04 | $85 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Oppenheimer | Outperform | maintained | $65.04 | $80 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Morgan Stanley | Overweight | maintained | $65.04 | $77 | running to 2028-04-21 | -11.3% |
| 2026-10-21 | JPMorgan | Overweight | maintained | $65.04 | $81 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | TD Cowen | Buy | reiterated | $65.04 | $100 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Piper Sandler | Overweight | maintained | $65.04 | $78 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Evercore ISI Group | Outperform | maintained | $65.04 | $90 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Barclays | Equal-Weight | maintained | $65.04 | $65 | within 5% of price when set | -11.3% |
| 2026-10-21 | Guggenheim | Buy | maintained | $65.04 | $78 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Citizens | Market Perform | reiterated | $65.04 | — | no target | -11.3% |
| 2026-10-21 | Wedbush | Outperform | maintained | $65.04 | $80 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Bernstein | Outperform | maintained | $65.04 | $80 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Rosenblatt | Neutral | maintained | $65.04 | $71 | running to 2027-10-21 | -11.3% |
| 2026-10-21 | Needham | Buy → Hold | downgrade | $65.04 | — | no target | -11.3% |
| 2026-10-21 | Bank of America | Buy | maintained | $65.04 | $90 | running to 2027-10-21 | -11.3% |
| 2026-10-16 | BMO Capital | Outperform | maintained | $70.53 | $125 | running to 2027-10-16 | -7.7% |
| 2026-10-16 | Wedbush | Outperform | maintained | $70.53 | $90 | replaced 2026-10-21, new $80 | -7.7% |
| 2026-10-16 | Rosenblatt | Neutral | maintained | $70.53 | $75 | replaced 2026-10-21, new $71 | -7.7% |
| 2026-10-13 | KeyBanc | Overweight | maintained | $70.46 | $85 | running to 2027-10-13 | -9.0% |
| 2026-10-08 | Morgan Stanley | Overweight | maintained | $71.57 | $80 | replaced 2026-10-21, new $77 | -6.8% |
| 2026-10-07 | Barclays | Equal-Weight | maintained | $69.70 | $70 | within 5% of price when set | -10.9% |
| 2026-10-05 | TD Cowen | Buy | reiterated | $67.50 | $100 | running to 2027-10-05 | -13.7% |
| 2026-10-01 | Guggenheim | Buy | maintained | $67.85 | $80 | replaced 2026-10-21, new $78 | -16.0% |
| 2026-09-29 | Deutsche Bank | Hold → Buy | upgrade | $70.30 | $95 | running to 2027-09-29 | -14.0% |
| 2026-09-22 | HSBC | Buy → Hold | downgrade | $72.16 | $76 | running to 2027-09-22 | -9.3% |
| 2026-09-18 | Wells Fargo | Equal-Weight → Underweight | downgrade | $71.79 | $57 | running to 2027-09-18 | -10.5% |
| 2026-09-14 | Evercore ISI Group | Outperform | maintained | $80.32 | $110 | replaced 2026-10-21, new $90 | +2.8% |
| 2026-08-25 | Wolfe Research | Outperform | maintained | $82.23 | $95 | running to 2027-08-25 | +17.3% |
| 2026-07-22 | Baird | Outperform | maintained | $68.53 | $90 | running to 2027-07-22 | -6.0% |
| 2026-07-17 | Goldman Sachs | Buy | maintained | $68.95 | $94 | running to 2027-07-17 | -10.4% |
| 2026-07-17 | Piper Sandler | Overweight | maintained | $68.95 | $85 | replaced 2026-10-21, new $78 | -10.4% |
| 2026-07-17 | JPMorgan | Overweight | maintained | $68.95 | $85 | replaced 2026-10-21, new $81 | -10.4% |
| 2026-07-17 | Morgan Stanley | Overweight | maintained | $68.95 | $83 | replaced 2026-10-08, new $80 | -10.4% |
| 2026-07-17 | KGI Securities | Outperform → Neutral | downgrade | $68.95 | $75 | reached 2026-08-10 | -10.4% |
| 2026-07-17 | Oppenheimer | Outperform | maintained | $68.95 | $85 | replaced 2026-10-21, new $80 | -10.4% |
| 2026-07-17 | Rosenblatt | Neutral | maintained | $68.95 | $75 | reached 2026-08-10 | -10.4% |
| 2026-07-17 | Wells Fargo | Equal-Weight | maintained | $68.95 | $80 | reached 2026-08-19 | -10.4% |
| 2026-07-17 | Evercore ISI Group | Outperform | maintained | $68.95 | $100 | replaced 2026-09-14, new $110 | -10.4% |
| 2026-07-17 | UBS | Buy | maintained | $68.95 | $115 | replaced 2026-10-21, new $100 | -10.4% |
| 2026-07-17 | Wedbush | Outperform | maintained | $68.95 | $105 | replaced 2026-10-16, new $90 | -10.4% |
| 2026-07-17 | Guggenheim | Buy | maintained | $68.95 | $75 | reached 2026-08-10 | -10.4% |
| 2026-07-17 | Barclays | Equal-Weight | maintained | $68.95 | $80 | reached 2026-08-19 | -10.4% |
| 2026-07-17 | TD Cowen | Buy | maintained | $68.95 | $100 | running to 2027-07-17 | -10.4% |
| 2026-07-17 | Bernstein | Outperform | maintained | $68.95 | $95 | replaced 2026-10-21, new $80 | -10.4% |
| 2026-07-17 | Pivotal Research | Hold | maintained | $68.95 | $70 | within 5% of price when set | -10.4% |
| 2026-07-15 | Guggenheim | Buy | reiterated | $73.68 | $120 | replaced 2026-07-17, new $75 | -9.8% |
| 2026-07-14 | Morgan Stanley | Overweight | reiterated | $73.53 | $90 | replaced 2026-07-17, new $83 | -8.5% |
| 2026-07-14 | Rosenblatt | Neutral | maintained | $73.53 | $95 | replaced 2026-07-17, new $75 | -8.5% |
| 2026-07-14 | Barclays | Equal-Weight | maintained | $73.53 | $85 | replaced 2026-07-17, new $80 | -8.5% |
| 2026-07-13 | Oppenheimer | Outperform | maintained | $73.83 | $100 | replaced 2026-07-17, new $85 | -8.1% |
| 2026-07-13 | KeyBanc | Overweight | maintained | $73.83 | $92 | replaced 2026-10-13, new $85 | -8.1% |
| 2026-07-09 | Citigroup | Buy | maintained | $75.47 | $100 | replaced 2026-10-21, new $85 | -7.3% |
| 2026-07-08 | Bernstein | Outperform | maintained | $75.59 | $100 | replaced 2026-07-17, new $95 | -8.5% |
| 2026-05-18 | Bank of America | Buy | reiterated | $89.65 | $125 | replaced 2026-10-21, new $90 | -7.9% |
| 2026-05-15 | Guggenheim | Buy | reiterated | $87.02 | $120 | replaced 2026-07-17, new $75 | -19.2% |
| 2026-04-17 | Piper Sandler | Overweight | maintained | $97.31 | $115 | replaced 2026-07-17, new $85 | +2.8% |
| 2026-04-17 | Oppenheimer | Outperform | maintained | $97.31 | $120 | replaced 2026-07-13, new $100 | +2.8% |
| 2026-04-17 | Barclays | Equal-Weight | maintained | $97.31 | $110 | replaced 2026-07-14, new $85 | +2.8% |
| 2026-04-17 | Citizens | Market Perform | reiterated | $97.31 | — | no target | +2.8% |
| 2026-04-17 | KeyBanc | Overweight | reiterated | $97.31 | $115 | replaced 2026-07-13, new $92 | +2.8% |
| 2026-04-17 | Wedbush | Outperform | reiterated | $97.31 | $118 | replaced 2026-07-17, new $105 | +2.8% |
| 2026-04-17 | Rosenblatt | Neutral | maintained | $97.31 | $95 | within 5% of price when set | +2.8% |
| 2026-04-17 | Guggenheim | Buy | maintained | $97.31 | $120 | replaced 2026-07-17, new $75 | +2.8% |
| 2026-04-15 | Citizens | Market Perform | reiterated | $107.71 | — | no target | +13.1% |
| 2026-04-14 | Guggenheim | Buy | reiterated | $106.28 | $130 | replaced 2026-04-17, new $120 | +11.5% |
| 2026-04-14 | KeyBanc | Overweight | maintained | $106.28 | $115 | replaced 2026-07-13, new $92 | +11.5% |
| 2026-04-13 | Wedbush | Outperform | maintained | $103.16 | $118 | replaced 2026-07-17, new $105 | +8.2% |
| 2026-04-06 | Rosenblatt | Neutral | maintained | $98.93 | $96 | within 5% of price when set | -0.1% |
| 2026-04-06 | Goldman Sachs | Neutral → Buy | upgrade | $98.93 | $120 | replaced 2026-07-17, new $94 | -0.1% |
| 2026-03-30 | Citizens | Market Perform | initiated | $92.97 | — | no target | -3.4% |
| 2026-03-27 | Oppenheimer | Outperform | maintained | $93.43 | $135 | replaced 2026-04-17, new $120 | +13.0% |
| 2026-03-06 | CFRA | Hold → Buy | upgrade | $99.02 | $115 | running to 2027-03-06 | +23.5% |
| 2026-03-06 | Bank of America | Buy | maintained | $99.02 | $125 | replaced 2026-10-21, new $90 | +23.5% |
| 2026-03-02 | JPMorgan | Neutral → Overweight | upgrade | $97.09 | $120 | replaced 2026-07-17, new $85 | +16.3% |
| 2026-02-27 | Rosenblatt | Neutral | maintained | $96.24 | $95 | within 5% of price when set | +13.7% |
| 2026-02-20 | Wedbush | Outperform | reiterated | $78.67 | $115 | replaced 2026-04-13, new $118 | -7.8% |
| 2026-01-27 | Freedom Broker | Hold → Buy | upgrade | $85.58 | $104 | reached 2026-04-14 | -9.4% |
| 2026-01-22 | Argus Research | Buy | maintained | $83.54 | $110 | replaced 2026-10-22, new $95 | -10.7% |
| 2026-01-21 | Oppenheimer | Outperform | maintained | $85.36 | $125 | replaced 2026-03-27, new $135 | -8.4% |
| 2026-01-21 | Deutsche Bank | Hold | maintained | $85.36 | $98 | reached 2026-03-04 | -8.4% |
| 2026-01-21 | TD Cowen | Buy | maintained | $85.36 | $112 | replaced 2026-07-17, new $100 | -8.4% |
| 2026-01-21 | Piper Sandler | Overweight | reiterated | $85.36 | $103 | reached 2026-04-10 | -8.4% |
| 2026-01-21 | Wolfe Research | Outperform | maintained | $85.36 | $95 | reached 2026-02-27 | -8.4% |
| 2026-01-21 | UBS | Buy | maintained | $85.36 | $130 | replaced 2026-07-17, new $115 | -8.4% |
| 2026-01-21 | Wedbush | Outperform | reiterated | $85.36 | $115 | replaced 2026-04-13, new $118 | -8.4% |
| 2026-01-21 | KeyBanc | Overweight | maintained | $85.36 | $108 | replaced 2026-04-14, new $115 | -8.4% |
| 2026-01-21 | Canaccord Genuity | Buy | maintained | $85.36 | $125 | running to 2027-01-21 | -8.4% |
| 2026-01-21 | BMO Capital | Outperform | maintained | $85.36 | $135 | replaced 2026-10-16, new $125 | -8.4% |
| 2026-01-21 | Morgan Stanley | Overweight | maintained | $85.36 | $110 | replaced 2026-07-14, new $90 | -8.4% |
| 2026-01-21 | Guggenheim | Buy | maintained | $85.36 | $130 | replaced 2026-04-17, new $120 | -8.4% |
| 2026-01-21 | Rosenblatt | Neutral | maintained | $85.36 | $94 | reached 2026-02-27 | -8.4% |
| 2026-01-21 | Needham | Buy | maintained | $85.36 | $120 | running to 2027-01-21 | -8.4% |
| 2026-01-21 | Goldman Sachs | Neutral | maintained | $85.36 | $100 | replaced 2026-04-06, new $120 | -8.4% |
| 2026-01-21 | Pivotal Research | Hold | maintained | $85.36 | $95 | reached 2026-02-27 | -8.4% |
| 2026-01-16 | KeyBanc | Overweight | maintained | $88.00 | $110 | replaced 2026-01-21, new $108 | -7.2% |
| 2026-01-16 | Rosenblatt | Neutral | maintained | $88.00 | $105 | replaced 2026-01-21, new $94 | -7.2% |
| 2026-01-15 | Wedbush | Outperform | maintained | $88.05 | $115 | replaced 2026-04-13, new $118 | -6.9% |
| 2026-01-13 | TD Cowen | Buy | maintained | $90.32 | $115 | replaced 2026-01-21, new $112 | -5.1% |
| 2026-01-12 | HSBC | Buy | initiated | $89.41 | $107 | reached 2026-04-15 | -6.1% |
| 2026-01-05 | CFRA | Buy → Hold | downgrade | $91.46 | $100 | replaced 2026-03-06, new $115 | -8.8% |
| 2025-12-11 | Jefferies | Buy | maintained | $94.09 | $134 | running to 2026-12-11 | -17.2% |
| 2025-12-09 | Needham | Buy | reiterated | $96.71 | $150 | replaced 2026-01-21, new $120 | -12.4% |
| 2025-12-08 | Canaccord Genuity | Buy | maintained | $96.79 | $152 | replaced 2026-01-21, new $125 | -12.3% |
| 2025-12-08 | Pivotal Research | Buy → Hold | downgrade | $96.79 | $105 | replaced 2026-01-21, new $95 | -12.3% |
| 2025-12-08 | Rosenblatt | Buy → Neutral | downgrade | $96.79 | $105 | replaced 2026-01-21, new $94 | -12.3% |
| 2025-11-28 | Rosenblatt | Buy | maintained | $107.58 | $152 | replaced 2025-12-08, new $105 | -2.2% |
| 2025-11-18 | Barclays | Equal-Weight | maintained | $114.09 | $110 | within 5% of price when set | — |
| 2025-11-18 | JPMorgan | Neutral | maintained | $114.09 | $124 | replaced 2026-03-02, new $120 | — |
| 2025-11-03 | KGI Securities | Neutral → Outperform | upgrade | $110.01 | — | no target | — |
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.